Clinical trial · Interventional
Identification of Chemotherapy-induced Peripheral Neuropathy
Identification of Chemotherapy-induced Peripheral Neuropathy - A Self-administered Scoring System Tested in Breast Cancer Survivors
NCT07148336CI-TRIAL-00112839NEURO-BREACcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Symptom-based scoring system | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Breast cancer patients treated with taxane-base chemotherapy
- description
- Patients who were previously treated with taxane-base chemotherapy and adjuvant radiotherapy for breast cancer and developed either no or moderate to severe chemotherapy-induced peripheral neuropathy
- interventionNames
- Other: Symptom-based scoring system
Primary outcomes (1)
- measure
- Number of participants with moderate to severe chemotherapy-induced peripheral neuropathy
- timeFrame
- from enrollment to clinical examination at 1 week
- description
- Chemotherapy-induced peripheral neuropathy will be assessed with a symptom-based scoring system supported by a neuropathy tracker.
Secondary outcomes (1)
- measure
- Rate of patient satisfaction
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically proven breast cancer 2. Previous treatment with taxane-based chemotherapy followed by adjuvant radiotherapy 3. Moderate to severe or no CIPN according to the Utah Early Neuropathy Scale and the Total Neuropathy Score 4. Female gender 5. Age ≥18 years 6. Written informed consent 7. Capacity of the patient to consent Exclusion Criteria: 1. Disease-related skin disorders of the lower extremities (e.g., related to skin infections, bullous dermatoses, dermatitis, papulo-squamous skin disorders, or urticaria/erythema) 2. Pregnancy, Lactation 3. Expected non-compliance
References
Publications (0)
Data not yet available
No reference posted for this study.